Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duvillard, L.
Right arrow Articles by Vergès, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duvillard, L.
Right arrow Articles by Vergès, B.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:1540-1544, 2003
© 2003 by the American Diabetes Association, Inc.

Pathophysiology/Complications
Original Article

Cell Surface Expression of LDL Receptor Is Decreased in Type 2 Diabetic Patients and Is Normalized by Insulin Therapy

Laurence Duvillard, MD, PHD1, Emmanuel Florentin, PHD1, Gérard Lizard, PHD1, Jean-Michel Petit, MD1,2, Françoise Galland2, Serge Monier1, Philippe Gambert, MD, PHD1 and Bruno Vergès, MD1,2

1 Unity INSERM 498, Hôpital du Bocage, Dijon Cédex, France
2 Department of Endocrinology and Metabolic Diseases, Hôpital du Bocage, Dijon Cédex, France

OBJECTIVE—In type 2 diabetic patients with poor metabolic control, kinetic studies have demonstrated that LDL fractional catabolic rate (FCR) is slowed down, whereas it is normalized on insulin therapy. This study was designed to analyze whether variations in the expression of LDL receptors at the cell surface could explain the results observed in kinetic studies.

RESEARCH DESIGN AND METHODS—LDL receptors were quantified at the surface of mononuclear cells in fresh fasting blood samples by a flow cytometry method in 21 control subjects and 21 type 2 diabetic patients before and 3 months after the introduction of insulin therapy and concomitant removal of oral antidiabetic drugs.

RESULTS—Before insulin treatment, monocyte LDL receptor expression was reduced by 41% (6,439 ± 2,310 vs. 10,846 ± 2,764 receptors per monocyte, P < 0.001) in type 2 diabetic patients compared with control subjects. It increased by 57% after 3 months of insulin therapy (10,096 ± 5,657 vs. 6,439 ± 2,310, P < 0.01) and was similar to that observed in control subjects.

CONCLUSIONS—Our results suggest that insulin plays an important role in the in vivo expression of LDL receptors. Moreover, modulations in the expression of LDL receptors in type 2 diabetic patients either with poor metabolic control or on insulin therapy are likely to contribute to the variations of LDL FCR demonstrated by kinetic studies under those circumstances.

Abbreviations: FCR, fractional catabolic rate • FITC, fluorescein isothiocyanate


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.